Valneva SEVALNNASDAQ

Overview Intelligence Charts News Fundamentals

Latest News

globenewswire.com

Valneva to Participate in Upcoming Investor Conferences

Lyon (France), March 2, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced its senior management will present and meet with investors at upcoming investor conferences in the United States and Europe. CEO Thomas Lingelbach and CFO Peter Buhler will discuss the Company's key value drivers and upcoming catalysts, including the topline Phase 3 data readout for VLA15, the Company's Lyme disease vaccine candidate, which partner Pfizer expects to report in the first half of 2026.

globenewswire.com

Valneva Reports Preliminary Unaudited 2025 Revenue and Cash and Provides 2026 Outlook

Lyon (France), February 19, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) a specialty vaccine company, today reported its preliminary unaudited full-year 2025 revenue and cash results1 and provided a first outlook for 2026.

globenewswire.com

Valneva Provides Update on Recommendations for Use of IXCHIQ® in the United Kingdom

Lyon (France), February 13, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that following a review of the benefits and risks of the Company's single‑dose chikungunya vaccine, IXCHIQ®, the United Kingdom's (UK) Commission on Human Medicines (CHM) has updated its recommendations for use of the vaccine. The updated Prescribing Information (PI) will reflect these recommendations, which now include a restriction for individuals over 60 years of age, for people with specified health conditions, as well as timing of vaccination prior to travel.

globenewswire.com

VALNEVA Declaration of shares and voting rights: January 31, 2026

Registered office: Îlot Saint-Joseph Bureaux Convergence – Bât. A, 12 ter Quai Perrache – 69002 Lyon.

globenewswire.com

Valneva and Instituto Butantan Announce Initiation of a Pilot Vaccination Campaign in Brazil with Single-Shot Chikungunya Vaccine IXCHIQ®

Lyon (France), Sao Paulo, (Brazil), February 3, 2026 –Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company and Instituto Butantan, one of the world's largest biomedical research centers, today announced the initiation of a Pilot Vaccination Strategy (PVS) in Brazil using Valneva's single-shot chikungunya vaccine, IXCHIQ®. The pilot vaccination program will serve as the basis for post-marketing commitment studies evaluating the effectiveness and safety of IXCHIQ® in a real-world setting and generating real-world evidence in a large population.

defenseworld.net

Valneva (NASDAQ:VALN) Shares Gap Down – Should You Sell?

Valneva SE Sponsored ADR (NASDAQ: VALN - Get Free Report) gapped down before the market opened on Friday. The stock had previously closed at $10.30, but opened at $9.97. Valneva shares last traded at $10.0190, with a volume of 1,646 shares changing hands. Analysts Set New Price Targets Several equities analysts have issued reports on

reuters.com

Valneva withdraws application for standard US approval of its chikungunya shot

French drugmaker Valneva said on Monday it has voluntarily withdrawn its application seeking standard approval of its chikungunya vaccine in the United States after the FDA suspended the shot's license in August, citing safety concerns.

globenewswire.com

Valneva Provides Update on Chikungunya Vaccine IXCHIQ®

Saint Herblain (France), January 19, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the Company has decided to voluntarily withdraw the biologics license application (BLA) and Investigational New Drug (IND) application for its chikungunya vaccine, IXCHIQ®, in the United States, following suspension of the license by the U.S. Food and Drug Administration (FDA) in August 2025. The Company had been awaiting further information with respect to its formal response to the vaccine license suspension. Valneva was recently informed of the FDA's further decision to now place the Investigational New Drug (IND) on clinical hold pending an investigation of a newly reported foreign Serious Adverse Event (SAE).

globenewswire.com

Valneva to Meet with Investors during the J.P. Morgan Healthcare Conference

Saint Herblain (France), January 09, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that members of its management team will meet one-on-one with existing shareholders and hold meetings with other institutional specialist investors during the 44th Annual J.P. Morgan Healthcare Conference, January 12-14, 2026, in San Francisco.

globenewswire.com

Valneva rencontrera des investisseurs lors de la J.P. Morgan Healthcare Conference

Saint Herblain (France), le 9 janvier 2026 - Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), société spécialisée dans les vaccins, a annoncé aujourd'hui que des membres de son équipe dirigeante rencontreront les actionnaires actuels de la Société et des investisseurs institutionnels spécialistes du secteur de la santé du 12 au 14 janvier 2026 lors de la 44e « J.

globenewswire.com

Valneva SE - Declaration of voting rights - December 2025

Registered office: Îlot Saint Joseph Bureaux Convergence – 12T Quai Perrache – 69002 Lyon

defenseworld.net

Valneva (NASDAQ:VALN) Trading Up 4.9% – Still a Buy?

Valneva SE Sponsored ADR (NASDAQ: VALN - Get Free Report) was up 4.9% during trading on Wednesday. The stock traded as high as $8.78 and last traded at $8.7590. Approximately 33,647 shares traded hands during mid-day trading, a decline of 45% from the average daily volume of 60,685 shares. The stock had previously closed at

globenewswire.com

Valneva and Serum Institute of India Announce Discontinuation of Chikungunya Vaccine License Agreement

Saint-Herblain (France), Pune, (India), December 31, 2025 – Valneva SE (“Valneva” or “the Company”), a specialty vaccine company, and Serum Institute of India (SII), a Cyrus Poonawalla Group company today announced that they have mutually agreed to discontinue their license agreement for Valneva's single-shot chikungunya vaccine.

globenewswire.com

Valneva Reports Positive Final Phase 2 Antibody Persistence and Safety Results in Children for its Chikungunya Vaccine IXCHIQ®

Saint-Herblain (France), December 10, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced positive final antibody persistence and safety data for its Phase 2 clinical trial evaluating the safety and immunogenicity of two different dose levels of its single-shot chikungunya vaccine, IXCHIQ®, in 304 children, twelve months after vaccination. Partially funded by the Coalition for Epidemic Preparedness Innovations (CEPI), with support from the European Union, the trial results continue to support future Phase 3 development in children, which the Company plans to initiate after gathering additional real-world experience in the adolescent population.

globenewswire.com

VALNEVA Declaration of shares and voting rights: November 30, 2025

Registered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France).

benzinga.com

Valneva Posts Positive Lyme Vaccine Booster Results — Pfizer Targeting 2026 Regulatory Filings

Valneva SE (NASDAQ: VALN) shared final immunogenicity and safety data on Wednesday from the Phase 2 study, VLA15-221, of the Lyme disease vaccine candidate, VLA15.

globenewswire.com

Valneva to Further Consolidate its Operations in France

Saint- Herblain (France), November 26 , 202 5 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced a strategic initiative to optimize its organizational footprint in France as part of the Company's ongoing efforts to increase operational effectiveness and position Valneva for long-term success.

wsj.com

Valneva Shares Rise on Positive Data from Lyme Disease Vaccine Study

Valneva said that antibody levels remained well above baseline across all six Lyme disease serotypes and all age groups in the trial.

globenewswire.com

Valneva annonce des résultats finaux positifs de Phase 2 pour son candidat vaccin contre la maladie de Lyme

Les taux d'anticorps sont restés supérieurs à leur niveau initial pour les six sérotypes et dans toutes les tranches d'âge six mois après la dernière injection des trois doses de rappel Aucun problème de sécurité n'a été observé dans toutes les tranches d'âge par le comité indépendant de surveillance des données (DMC) Ces résultats confirment le bénéfice d'une vaccination annuelle avant chaque saison de Lyme Saint-Herblain (France), le 26 novembre 2025 - Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) a annoncé aujourd'hui des données positives finales d'immunogénicité et d'innocuité pour l'étude de Phase 2 (VLA15-221) du candidat vaccin contre la maladie de Lyme, VLA15.

globenewswire.com

Valneva Announces Positive Final Phase 2 Results for Lyme Disease Vaccine Candidate

Saint-Herblain (France), November 26, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced positive final immunogenicity and safety data from Phase 2 study, VLA15-221, of Lyme disease vaccine candidate, VLA15. The results showed strong anamnestic immune response and favorable safety profile six months after a third booster dose (month 48) in all age groups, confirming compatibility with the anticipated benefits of a yearly vaccination prior to each Lyme season. Pfizer and Valneva entered into a collaboration agreement in April 2020 for the development and commercialization of VLA15 by Pfizer.

Loading news...

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance